FDA Panel Endorses Guardant's Colon Cancer Blood Test

An FDA advisory panel has recommended approval of Guardant Health's Shield blood test for colorectal cancer screening, citing its safety and effectiveness. The test, which detects DNA from tumors in blood samples, could provide a less invasive alternative to colonoscopies and stool tests, potentially increasing screening rates. However, concerns remain about its ability to detect precancerous lesions and the possibility of false negatives. The FDA is expected to decide on the approval in 2024.